Supported by Synergy Pharmaceuticals Inc.,which provided the funding and the plecanatide,dolcanatide and placebo used for these studies
AIM To investigate the effects of plecanatide and dolcanatide on maintenance of paracellular permeability, integrity of tight junctions and on suppression of visceral hypersensitivity. METHODS Transport of fluorescein...
Supported by National Cancer Institute(CA133689 to Kunwar Shailubhai,CA006927 to Fox Chase Cancer Center);an appropriation from the Commonwealth of Pennsylvania(Fox Chase Cancer Center)
AIM To evaluate the effect of orally administered plecanatide on colorectal dysplasia in Apc^(+/Min-FCCC) mice with dextran sodium sulfate(DSS)-induced inflammation. METHODS Inflammation driven colorectal carcinogenes...
Supported by NIH,No.R01CA170533,No.R01CA206026 and No.P30CA56036;Targeted Diagnostic and Therapeutics,Inc.;a Ruth L.Kirschstein National Research Service Award for Individual Predoctoral MD/PhD Fellows from the NIH,No.CA180500(To Blomain ES);a Ruth L.Kirschstein National Research Service Award for Individual Predoctoral MD/PhD Fellows from the NIH,No.F30 DK103492(To Merlino DJ);a Predoctoral Fellowship in Pharmacology/Toxicology from the PhR MA Foundation
Colorectal cancer(CRC) is a major cause of cancerrelated mortality and morbidity worldwide. While improved treatments have enhanced overall patient outcome, disease burden encompassing quality of life, cost of care, a...